Pilsicainide hydrochloride
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
88069-49-2Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2.ClNZOSVDHCTCLGEB-UHFFFAOYSA-N88069-49-2DTXSID7057860CHEMBL4303511安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
説明Pilsicainide hydrochloride is a new pynolizidine lidocaine derivative with antiarrhythmic activity. It is the first pharmaceutical product introduced by Suntory and was solely developed in Japan. The compound is reported to be highly effective in the treatment of premature ventricular contraction. It has no anticholinergic or CNS activity and is not as likely as other class 1C antiarrhythmics to have restricted indications.
使用Pilsicainide hydrochloride has been used as a sodium channel blocker:to study its effects on electrophysiological parameters in guinea pig pulmonary vein preparationto study its effects on Ca2+release and arrhythmic events in Andersen-Tawil syndrome induced pluripotent stem cells (ATS-iPSC)-derived cardiomyocytesto study its electrophysiological effects on the guinea pig atrium
現在のフィルター条件では反応記録がありません。
読み込み中…